GSK
Former Novartis man becomes GSK’s new medical director
May 8, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GSK, James Shannon, Novartis
James Shannon has been named GSK’s chief medical officer, and will report to R&D chairman Moncef Slaoui. He will be …
GSK signs deal with academics
May 4, 2012Research and Development, Sales and Marketing Cancer, GSK, PROTAC, Yale, academia
GlaxoSmithKline has forged another link with academia, signing a deal with Yale University to design a potential new class of …
GSK appoints two non-executive directors to its Board
May 3, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GSK, Jing Ulrich, Lynn Elsenhans
GlaxoSmithKline has announced that Lynn Elsenhans and Jing Ulrich will join the Board of the Company with effect from 1 …
FDA approves GSK’s Votrient for new licence
April 30, 2012Sales and Marketing Cancer, FDA Approval, GSK, Votrient
The FDA has approved GlaxoSmithKline’s cancer pill Votrient for the treatment of a rare group of cancers – but has …
NICE no to GSK’s lupus drug Benlysta
April 27, 2012Sales and Marketing Andrew Dillon, Benlysta, GSK, Lupus, NICE
NICE is still not recommending GlaxoSmithKline’s lupus drug Benlysta, as it believes the treatment is too costly. In its final …
Novartis to invest $550m in new Swiss plant
April 24, 2012Manufacturing and Production GSK, Novartis, manufacturing and production
Novartis has unveiled plans to build a new manufacturing facility at its site in Stein, Switzerland, just weeks after calling …
GSK’s bid for Human Genome Sciences rejected
April 19, 2012Sales and Marketing Benlysta, GSK, Human Genome Sciences, mergers and acquisitions
GlaxoSmithKline has launched a takeover bid for Human Genome Sciences for around $2.5 billion, but has been rejected by the …
GSK’s diabetes drug misses goal
April 4, 2012Research and Development, Sales and Marketing Bydureon, GSK, Victoza, albiglutide, diabetes
GlaxoSmithKline has insisted its new long-acting Type 2 diabetes drug albiglutide remains on course for filing following topline results from …
Roche to submit Herceptin successor to regulators
April 2, 2012Research and Development, Sales and Marketing GSK, Herceptin, Roche, Xeloda
Roche has said it will submit its new breast cancer drug trastuzumab for regulatory review in the US and Europe …
GSK settles cancer patent dispute
March 28, 2012Research and Development, Sales and Marketing GSK, Genmab, Roche, ofatumumab, patents
GlaxoSmithKline has settled a long-running patent dispute over its cancer treatment ofatumumab. The US patents, which relate to recombinant antibody …
Early-stage research gains another funding boost
March 23, 2012Research and Development, Sales and Marketing GSK, Index Ventures, Janssen, R&D
GlaxoSmithKline and Janssen are among the key investors in a venture capital fund aimed solely at identifying promising pharma start-ups. …
GSK selects Ulverston for biopharma manufacturing hub
March 22, 2012Manufacturing and Production, Research and Development, Sales and Marketing Cameron, GSK, Ulverston, manufacturing
GlaxoSmithKline has announced the long-awaited decision on the location of its biopharmaceutical plant in the UK, with Ulverston in Cumbria …
British biotech industry gains £200m boost
March 21, 2012Research and Development, Sales and Marketing GSK, Wellcome Trust, biotech, fund
The Wellcome Trust is to launch a £200 million business that will invest in emerging healthcare and life sciences firms. …
GSK sells off OTC products
March 16, 2012Sales and Marketing GSK, OTC, Omega Pharma, Zantac
GlaxoSmithKline has shed more of its non-core consumer health OTC products in a £391 million sale, including a German manufacturing …
GSK chooses Infosys and Fabric Worldwide for digital platform
March 15, 2012Medical Communications, Sales and Marketing Fabric Worldwide, GSK, Infosys, digital
GlaxoSmithKline has hired two technology companies to help it optimise digital communications in consumer healthcare and pharmaceuticals.The firm will work …
Latest content
ESTEVE CDMO adds $17.5m to Illinois expansion
Brenntag and dsm-firmenich expand biopharma vitamin partnership
